harissa hasbullah

harissa hasbullah


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Thoracic Cancer
Verified
Journal Article
Open access
SHSoon Hin How
Soon Hin How
LTLye Mun Tho
Lye Mun Tho
CLChong Kin Liam
Chong Kin Liam
HHharissa hasbullah
harissa hasbullah
GHGwo Fuang Ho
Gwo Fuang Ho
SSSing Yang Soon
Sing Yang Soon
Introduction: Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non‐small‐cell lung cancer (NSCLC) and programmed death ligand‐1 (PD‐L1) expression is a recognized biomarker to determine response to therapy. We retrospectively analyzed NSCLC patients in the Malaysia Lung Cancer Registry (MLCR) and report on the clinical characteristics associated with PD‐L1 expression and ICI use in Malaysia, a low‐ to middle‐income country.Methods: All 901 NSCLC patients in the MLCR who were diagnosed from January 1, 2017 to December 31, 2020 from 14 hospitals across the country were analyzed.Results: Out of 901 patients, 505 had PDL‐1 testing done with complete data available only in 489 patients. The most common histology was adenocarcinoma (84.7%) followed by squamous cell carcinoma (10.2%). The majority (95%) presented with stage 3 or 4. The number and percentage of patients with PDL‐1 tumor proportion scores of ≥50%, 1–49%, and <1% were 138 (28.2%), 158 (32.3%), and 193 (39.5%), respectively. In multivariate analysis, the presence of genomic mutation is the only independent characteristic associated with negative PD‐L1 expression (crude odds ratio 0.579, 95% confidence interval 0.399–0.840, p = 0.004). Of 292 patients eligible for ICI therapy, only 100 patients (34.2%) received ICIs. Seventy‐eight patients received ICI therapy as first‐line treatment, 15 patients as second‐line treatment, and 7 patients as third‐line treatment.Conclusions: This is the first analysis on PD‐L1 expression and ICI use in Malaysia. Despite the proven efficacy of ICI therapy, only 56% of our patients had PD‐L1 tests performed and only 34.2% of eligible patients received ICIs.

8 June 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
HHharissa hasbullah
harissa hasbullah
FMFarah Wahida MdYusof
Farah Wahida MdYusof
AAAmirah Hayati Ahmad
Amirah Hayati Ahmad
OAOmar Alzallal
Omar Alzallal
SSSharifah Emilia T. T Sharif
Sharifah Emilia T. T Sharif
Prostate cancer is common in men, but tumour of the male breast is rare. For these two tumours to be presented synchronously in a male patient is even rarer. The focus of this paper is the case of a 72-year-old man diagnosed with papillary ductal carcinoma in situ after he presented with a unilateral breast mass associated with nipple discharge. Imaging staging for his breast tumour and subsequent prostate biopsy found an incidental synchronous asymptomatic prostate adenocarcinoma as well as bone metastases. He denies risk factors for malignancies and refuses genetic testing. The first part of our discussion will highlight the uncommon occurrence of male breast ductal carcinoma in situ and its management controversies. The subsequent part of our discussion will focus on the association between male breast cancer and prostate cancer, and implication of this on the future treatment of these patients. More importantly, our case will illustrate the challenges in managing dual primaries that present concurrently.

16 February 2022 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
HSHans Prakash Sathasivam
Hans Prakash Sathasivam
SCSelina Yuet Ling Chew
Selina Yuet Ling Chew
WKWee‐Ric Kim
Wee‐Ric Kim
CSChee‐Lynn Saw
Chee‐Lynn Saw
LTLu Ping Tan
Lu Ping Tan
AKAlan Khoo
Alan Khoo